Loading clinical trials...

Clinical Observation of Long-term Efficacy and Safety of Glycyrrhizic Acid Preparation in the Therapy of Autoimmune Liver Disease | Clinical Trials | Clareo Health

COMPLETED

Clinical Observation of Long-term Efficacy and Safety of Glycyrrhizic Acid Preparation in the Therapy of Autoimmune Liver Disease

Clinical Observation of Long-term Efficacy and Safety of Glycyrrhizic Acid Preparation in the Treatment of Autoimmune Liver Disease

NCT04028869•Beijing Ditan Hospital

View on ClinicalTrials.gov

Summary

This study was a retrospective clinical observation cohort study. All patients with autoimmune liver disease treated with glycyrrhizic acid preparations in the Department of Liver Diseases, Department of Liver Diseases, Beijing Ditan Hospital, Capital Medical University, were enrolled. Clinical follow-up data including demographics, hematuria, and liver and kidney were collected. Functional, electrolyte blood glucose, PTA, erythrocyte sedimentation rate, serum AFP and other clinical biochemical indicators and autoantibodies, special proteins and liver imaging (liver ultrasound) examination. The clinical effect of glycyrrhizic acid preparation for the treatment of autoimmune liver disease for 144 weeks and the safety during treatment were analyzed.

Detailed Description

Eligibility

Age

18 - 75 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1\) Patients with autoimmune liver disease: All enrolled autoimmune liver diseases meet the diagnostic criteria of China's Consensus on Diagnosis and Treatment of Autoimmune Liver Disease (2015);
•2\) no hormones and / or immunosuppressants and other liver protection drugs;
•3\) Sign the written informed consent form.

Exclusion Criteria

•1\) Combine other hepatitis virus (HCV, HDV) infections;
•2\) viral liver disease;
•3\) HIV infection;
•4\) long-term alcohol abuse and / or other liver damage drugs;
•5\) mental illness;
•6\) Evidence of liver tumors (liver cancer or AFP \> 100 ng/ml);
•7\) decompensated cirrhosis;
•8\) Serious diseases such as heart, brain, lung, kidney, etc. can not participate in long-term follow-up;
•9\) There are hormones and / or immunosuppressants and other liver protection drugs.

Locations (1)

liver disease center, Beijing Ditan Hospital

Beijing, Beijing Municipality, China

Key Dates

Start Date

March 1, 2018

Primary Completion Date

March 30, 2019

Completion Date

March 30, 2019

Last Updated

July 23, 2019

Enrollment

400

ACTUAL participants

Conditions

Autoimmune Liver Disease

Interventions

Glycyrrhizic acid preparation

DRUG

PredIcting SterOid DepeNdEnt LivEr InjuRy with Polyreactive Immunoglobulin G

NCT05810480

Autoimmune HepatitisAutoimmune Liver Disease

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 23, 2019Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions